Skip to main content
. 2022 Oct 14;15(2):307–325. doi: 10.1016/j.jcmgh.2022.10.005

Figure 1.

Figure 1

Elevated HDLBP expression is associated with the prognosis of patients with HCC.A, The FPKM levels of HDLBP from TCGA-LIHC and ICGC-LIHC datasets. FPKM, Fragments per kilobase of exon model per million mapped fragments. B, The FPKM levels of HDLBP from GSE17967 datasets. CIR, cirrhosis. C, Representative images of IHC staining (left panel) of HCC samples with different HDLBP expression levels. Scale bars, 50 μm. Analysis of the relative expression (right panel) of HDLBP in HCC and NCL tissues. D, Representative images of IHC staining of HCC samples with different HDLBP levels. Scale bars, 50 μm. E, Representative images of IHC staining for HDLBP from the Human Protein Atlas. Scale bars, 50 μm. F, qRT-PCR analysis of HDLBP expression in primary hepatocytes (PHs) and 5 established HCC cell lines (Hep3B, Huh7, SNU182, SNU387, and HepG2). G, Immunoblots (upper panel) and relative quantitative analysis (lower panel) of HDLBP levels in PH and established HCC cell lines. H, Kaplan-Meier curves were constructed to assess the correlation between HDLBP expression and overall survival (OS) of patients with HCC from TCGA-LIHC and ICGC-LIHC datasets. HDLBP expression was categorized as “high” or “low” using the median value as the cutoff point. For all the experiments described above, the data in A, B, F, and G are presented as the means ± standard deviations (SDs), and 3 independent experiments (N = 3) were performed in triplicate. ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001.